External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
M. Bolla(Centre Hospitalier Universitaire de Grenoble), Laurence Collette(GlaxoSmithKline (Belgium)), Cora N. Sternberg(Cornell University), José Lopez Torecilla(Fundación Instituto Valenciano de Oncología), Guy Storme(Mathys (Netherlands)), Abraham Kuten(Rambam Health Care Campus), Carmel Lino Cutajar, Geertjan van Tienhoven, Theodorus van der Kwast(Erasmus MC), Jacques Bernier(Ospedale San Giovanni Bellinzona), René‐Olivier Mirimanoff(University of Lausanne), Raphael Pfeffer, Padraig Warde(University Health Network), J.B. Dubois(CEA Valduc), Ignace Billiet(AZ Groeninge)
Cited by 944
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k